Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

Narendranath Epperla*, Jeffrey Switchenko, Veronika Bachanova, James N. Gerson, Stefan K. Barta, Max J. Gordon, Alexey V. Danilov, Natalie S. Grover, Stephanie Mathews, Madelyn Burkart, Reem Karmali, Yazeed Sawalha, Brian T. Hill, Nilanjan Ghosh, Steven I. Park, David A. Bond, Mehdi Hamadani, Timothy S. Fenske, Peter Martin, Mary Kate MalecekBrad S. Kahl, Christopher R. Flowers, Brian K. Link, Lawrence D. Kaplan, David J. Inwards, Andrew L. Feldman, Eric D. Hsi, Kami Maddocks, Kristie A. Blum, Nancy L. Bartlett, James R. Cerhan, John P. Leonard, Thomas M. Habermann, Matthew J. Maurer, Jonathon B. Cohen

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


The prognostic relevance of diagnosis to treatment interval (DTI) in patients with newly diagnosed mantle cell lymphoma (MCL) is unknown. Hence, we sought to evaluate the impact of DTI on outcomes in MCL using 3 large datasets (1) the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource, (2) patients enrolled in the ALL Age Asthma Cohort/CALGB 50403, and (3) a multisitecohort of patients with MCL. Patients were a priori divided into 2 groups, 0 to 14 days (short DTI) and 15 to 60 days (long DTI). The patients in whom observation was deemed appropriate were excluded. One thousand ninety-seven patients newly diagnosed with MCL and available DTI were included in the study. The majority (73%) had long DTI (n=797). Patients with short DTI had worse eastern cooperative oncology group performance status (ECOG PS ≥2), higher lactate dehydrogenase, bone marrow involvement, more frequent B symptoms, higher MCL International Prognostic Index (MIPI ≥6.2), and were less likely to receive intensive induction therapy than long DTI group. The median progression-free survival (2.5 years vs 4.8 years, p<0.0001) and overall survival (7.8 years vs. 11.8 years, p<0.0001) were significantly inferior in the short DTI group than the long DTI cohort and remained significant for progression-free survival and overall survival in multivariable analysis. We show that the DTI is an important prognostic factor in patients newly diagnosed with MCL and is strongly associated with adverse clinical factors and poor outcomes. DTI should be reported in all the patients newly diagnosed with MCL who are enrolling in clinical trials and steps must be taken to ensure selection bias is avoided.

Original languageEnglish (US)
Pages (from-to)2287-2296
Number of pages10
JournalBlood Advances
Issue number11
StatePublished - Jun 13 2023

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma'. Together they form a unique fingerprint.

Cite this